When US President Donald Trump threatened 200 per cent tariffs on foreign-made pharmaceuticals, investors responded like it was a placebo. It’s the latest spat between drugmakers and an administration that share a complicated relationship. The FT’s Hannah Kuchler and Patrick Temple-West explain why Trump and Big Pharma aren’t getting along, and what that prescribes for the future of the industry.Mentioned in this podcast:Email Marc your questions ([email protected])Investors shrug off Donald Trump’s 200% tariff on pharmaThe looming ‘patent cliff’ facing Big PharmaSign up for the FT’s Swamp Notes newsletter hereSwamp Notes is produced by Henry Larson. Topher Forhecz is the FT’s executive producer. The FT’s acting co-head of audio is Topher Forhecz. Special thanks to Pierre Nicholson. CREDIT: The White House, Roll CallRead a transcript of this episode on FT.com Hosted on Acast. See acast.com/privacy for more information.

Ver todos los episodios